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Abstract
Introduction The present study aimed to investigate changes of
the immune response between sepsis due to ventilator-
associated pneumonia (VAP) and sepsis due to other types of
infections.
Methods Peripheral venous blood was sampled from 68
patients with sepsis within 24 hours of diagnosis; 36 suffered
from VAP; 32 from other nosocomial infections, all well-matched
for severity, age and sex. Blood monocytes were isolated and
cultured with/without purified endotoxin (lipopolysaccharide
(LPS)). Estimation of tumour necrosis factor alpha (TNFα) and
interleukin-6 (IL-6) in cultures' supernatants was done by an
enzyme immunoassay. Flow cytometry was used to determine
subpopulations of mononuclear cells and apoptosis. To mimic
pathogenesis of VAP, mononuclear cells of healthy volunteers
were progressively stimulated with increased inocula of
pathogens; apoptosis was determined.
Results In patients with VAP, the absolute number of CD3(+)/
CD4(+) lymphocytes was significantly lower (P = 0.034) and
apoptosis of isolated monocytes was increased (P = 0.007)
compared to other infections. TNFα and IL-6 production from
LPS-stimulated monocytes was lower in patients with VAP-
related sepsis than with sepsis due to other infections.
Apoptosis of monocytes was induced after in vitro stimulation of
mononuclear cells by a mechanism mimicking VAP.
Conclusions Decrease of CD4-lymphocytes and
immunoparalysis of monocytes are characteristic alterations of
sepsis arising in the field of VAP.
Introduction
Sepsis is an important cause of admission and mortality in
intensive care units (ICU). In Europe, the Sepsis Occurrence
in Acutely Ill Patients study disclosed an ICU mortality rate
from sepsis ranging between 27% and 54% depending on the
severity [1]. In the USA, 215,000 deaths are reported annually
due to sepsis [2].
Ventilator associated pneumonia (VAP) is the most common
nosocomial infection and the leading cause of sepsis in the
ICU. Up to 28% of patients receiving mechanical ventilation
will eventually develop VAP, with a mortality rate of up to 70%
[3-7].
Various explanations have been proposed for the increased
mortality of patients with VAP. One previous study from our
group in a cohort of 90 patients with sepsis and VAP mainly
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caused by Gram-negative bacteria disclosed an association
between derangements of the innate immune system and mor-
tality. More precisely, patients with early monocyte apoptosis
greater than 50% were less likely to die compared with those
exhibiting monocyte apoptosis lower than 50% [8]. However,
it was not studied whether apoptosis of monocytes is the only
detrimental alteration of the immune response linked to final
outcome or if other changes of the adaptive immune system
may have an effect as well. It should also be noted that this lat-
ter study was focused on patients with sepsis due to VAP,
whereas sepsis of other infectious etiologies may differ in
terms of its immune responses.
The present study was designed to unravel the unique fea-
tures of the innate and adaptive immune responses of patients
with sepsis due to VAP compared with patients with sepsis
due to other infectious diseases and to propose a mechanism
mediating these differences.
Materials and methods
Study population
A total of 68 patients were enrolled in the study. Patients were
hospitalized in the second Department of Critical Care Medi-
cine and in the fourth Department of Internal Medicine of
ATTIKON University Hospital in Athens. The study was
approved by the Ethics Committee of the hospital. Written
informed consent was provided by patients or their relatives.
All patients were older than 18 years. Exclusion criteria
included neutropenia (≤500 neutrophils/μl), HIV infection or
oral intake of corticosteroids at a dose equal to or higher than
1 mg/kg equivalent prednisone for at least one month.
All sequential admissions with sepsis, severe sepsis or septic
shock were screened for enrolment during the period January
2006 to June 2007. Patients finally enrolled were those with
septic syndrome due to VAP and those with septic syndrome
caused by other types of infection, namely acute pyelonephri-
tis, primary bacteremia, intraabdominal infection, community-
acquired pneumonia (CAP) and hospital-acquired pneumonia
(HAP), provided that they were well-matched to patients with
VAP by age, sex, underlying conditions and disease severity.
Sepsis was defined as any microbiologically documented or
clinically diagnosed infection accompanied by at least two of
the following: core temperature above 38°C or below 36°C;
pulse rate above 90 beats/minute; respiratory rate above 20
breaths/minute or partial pressure of carbon dioxide (pCO2)
below 32 mmHg; and leukocytosis (white blood cells (WBC)
>12,000 cells/μl) or leukopenia (WBC <4000 cels/μl) or
presence of immature forms above 10% of total WBC count
[9,10].
Severe sepsis was defined as sepsis aggravated by the acute
dysfunction of at least one organ. Acute organ dysfunction
was defined as follows: acute respiratory distress syndrome,
as any value of partial oxygen pressure/fraction of inspired oxy-
gen (pO2/FiO2) less than 200 and diffuse bilateral infiltrations
in chest X-ray; acute renal failure, as the production of less
than 0.5 ml urine/kg/hour for at least two hours, provided that
the negative fluid balance of the patient was corrected; meta-
bolic acidosis, as any pH below 7.30 or any base deficit above
5 mEq/l and serum lactate at least more than twice the upper
normal value; and acute coagulopathy, as any platelet count
below 100,000 cells/μl or International Normalized Ratio
above 1.5 [9,10].
Septic shock was defined as sepsis accompanied by systolic
arterial pressure lower than 90 mmHg necessitating the
administration of inotropic agents [9,10].
Diagnosis of VAP was established if all the following criteria
were met: intubation and mechanical ventilation for at least 48
hours prior to diagnosis; a new or progressive infiltrate on a
chest X-ray; purulent tracheobronchial secretions; and Clinical
Pulmonary Infection Score (CPIS) more than six [11-14].
Acute pyelonephritis was diagnosed in any patient presenting
with all the following: fever, lumbar tenderness or radiological
findings consistent with acute pyelonephritis, and pyuria
defined as more than 10 WBCs/high power field or positive
(+3) dipstick of urine for leukocyte esterase [15].
A diagnosis of intraabdominal infection was made in patients
with temperature above 38°C or below 36°C, leukocytosis
(WBC >12,000 cells/μl) and radiological findings consistent
with an intraabdominal infection [15].
Primary bacteremia was defined as any positive blood culture
for Gram-positive or Gram-negative microorganisms in the
absence of any well-defined focus of infection, including intra-
vascular-access devices [15].
Criteria required for the diagnosis of CAP and HAP included
the presence of a new infiltrate on a chest X-ray along with two
of the following: fever, leukocytosis or leukopenia, and/or puru-
lent sputum. Pneumonia was considered as: CAP whenever
the patient did not report any past hospitalization for the past
90 days or stay in a long-term care facility; or HAP when pre-
senting more than 48 hours after hospital admission in any
patient not requiring mechanical ventilation [14-16].
Patients were followed up for 28 days. A complete diagnostic
work-up was performed comprising history, clinical examina-
tion, blood cell counts and biochemistry, blood cultures, chest
X-ray, and chest and/or abdominal computed tomography
scans if considered necessary. Quantitative cultures of urine
or tracheobronchial secretions (TBS) were performed and
interpreted as previously described [17] depending on the
patient's underlying infection. Within the first 24 hours of the
advent of signs of sepsis, 15 ml of heparinized peripheralAvailable online http://ccforum.com/content/13/6/R172
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venous blood was sampled after puncture of one forearm vein
under sterile conditions.
Laboratory techniques
For the flow cytometric analysis, red blood cells were lysed
with ammonium chloride 1 mM and WBCs were washed three
times with PBS (pH 7.2; Merck, Darmstadt, Germany). WBCs
were then stained with fluorocolour-conjugated monoclonal
antibodies against CD3, CD4, CD8, CD(16+56), CD19 and
with the protein annexin-V and propidium iodine (PI) (Immu-
notech, Marseille, France), and incubated for 15 minutes in the
dark. Fluorocolours used were fluorescein isothiocyanate
(FITC; emission 525 nm; Immunotech, Marseille, France), phy-
coerythrin (PE; emission 575 nm; Immunotech, Marseille,
France), ECD (emission 613 nm, Immunotech, Marseille,
France) and PC5 (emission 670 nm, Immunotech, Marseille,
France). The following combinations were applied: anti-
CD3(FITC)/CD4(PE), anti-CD3(FITC)/CD8(PE), anti-
CD3(FITC)/CD(16+56)(PE), anti-CD19(FITC), annexin-
V(FITC)/CD4(PE)/PI (PC5), and annexin-V(FITC)/anti-
CD8(PE)/PI(PC5). Cells that stained positive for annexin-V
and negative for PI were considered apoptotic.
Flow-cytometric analysis was performed on an EPICS XL/
MSL flow cytometer (Beckman Coulter Co, Miami, FL, USA)
with gating for mononuclears based on their characteristic for-
ward and side scattering.
For the isolation of monocytes, blood was layered over Ficoll
Hypaque (Biochrom, Berlin, Germany) and centrifuged. Iso-
lated peripheral blood mononuclear cells (PBMCs) were
washed three times with PBS (pH 7.2) and incubated with
RPMI 1640 media enriched with 10% fetal bovine serum
(FBS) and 2 mM glutamine, 100 U/ml penicillin G and 0.1 mg/
ml streptomycin (Sigma Co, St Louis, MO, USA) in 75 cm3
flasks. After one hour of incubation at 37°C in 5% CO2, non-
adherent cells were removed. Adherent monocytes were thor-
oughly washed with Hank's solution (Biochrom, Berlin, Ger-
many), harvested with a 0.25% trypsin/0.02%
ethylenediamine tetraacetic acid (EDTA) solution (Biochrom,
Berlin, Germany). Their purity was more than 95% as defined
after staining with anti-CD14 and analysis by a flow cytometer.
Isolated monocytes were counted in a Neubauer plate by
trypan blue exclusion of dead cells, distributed in two wells of
a 12-well plate and cultured with RPMI 1640 media supple-
mented with 10% FBS and 2 mM glutamine with or without
the addition of 10 ng/ml of purified endotoxin (lipopolysaccha-
ride (LPS)) derived from Escherichia coli O155:H5 (Sigma
Co, St Louis, MO, USA). After incubation for 24 hours at 37°C
in a 5% CO2 atmosphere, supernatants were collected and
stored at -70°C until assayed for cytokines.
Estimation of TNFα and IL-6 in supernatants was performed by
an ELISA (Diaclone, Paris, France). Lowest detection limits
were 15.75 pg/ml for TNFα and 6.25 pg/ml for IL-6. Concen-
trations were adjusted as pg/104 live cells.
In an attempt to explain our findings, PBMCs of healthy volun-
teers were exposed to isolates of TBS from patients with VAP
and to blood isolates of patients with bloodstream infections
enrolled in this study. Current theories attribute pathogenesis
of VAP to the aspiration of microbes colonizing the oropharynx
in the lower respiratory tract. According to the theories, bacte-
ria replicate gradually and when their growth surpasses a cer-
tain threshold then VAP develops [18,19]. In an attempt to
reproduce the above sequence of events in vitro, PBMCs
were isolated from five healthy volunteers as described above.
They were distributed in wells of a 12-well plate in RPMI 1640
media supplemented with 10% FBS and 2 mM glutamine, 100
U/ml penicillin G and 0.1 mg/ml streptomycin (Sigma Co, St
Louis, MO, USA). These PBMCs were stimulated by four dif-
ferent isolates: one of Acinetobacter baumannii and another of
Pseudomonas aeruginosa isolated at a count of 1 × 106 cfu/
ml or more from TBS of two different patients with VAP; and
one of A. baumannii and another of P. aeruginosa isolated
from blood of two different patients with bacteremia. All iso-
lates were grown for 12 hours in Mueller-Hinton broth (Oxoid
Ltd, London, UK) in a shaking-water bath at 37°C. Then a log-
phase inoculum of 5 × 107 cfu/ml was prepared in Mueller-
Hinton broth using the 0.5 standard of the McFarland climax.
Appropriate amounts of that inoculum were used for cell stim-
ulation in four different patterns, as follows.
Pattern A was non-stimulated PBMCs incubated for 4.75
hours in growth medium at 37°C in 5% CO2.
Pattern B was sequential stimulation in three steps mimicking
pathogenesis of VAP. In the first step, PBMCs were exposed
for 15 minutes at 37°C in 5% CO2 in 1 × 103 cfu/ml of each
of the VAP pathogens. Then the plate was centrifuged, super-
natants were discarded and the cell pellet was dissolved in 2.4
ml of growth medium. In the second step, the same procedure
as in the first step was repeated after two hours. In the third
step, after two hours of incubation at 37°C in a 5% CO2
atmosphere, PBMCs were stimulated with 1 × 106 cfu/ml of
each of the two pathogens for 30 minutes. These inocula were
selected for stimulation in an attempt to generate conditions of
bacterial growth similar to those existing in patients with VAP.
Then, the plate was centrifuged.
Pattern C was an abrupt stimulation with VAP pathogens. The
first two steps of pattern B were performed but instead of stim-
ulation with 1 × 103 cfu/ml inoculum, Mueller-Hinton broth was
added in the plates. The third step was repeated as in pattern
B.
Pattern D was an abrupt stimulation with pathogens causing
bacteremia mimicking the pathogenesis of bacteremia. After
incubation for 4.15 hours at 37°C in 5% CO2 PBMCs wereCritical Care    Vol 13 No 6    Pelekanou et al.
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exposed for 30 minutes to 1 × 106 cfu/ml of each of the two
pathogens causing bacteremia. Then the plate was centri-
fuged.
For all the above patterns, after centrifugation of the plate and
removal of supernatants, adherent cells were harvested with a
0.25% trypsin/0.02% EDTA solution (Biochrom, Berlin, Ger-
many). Flow cytometric analysis of apoptosis was performed
after staining collected cells with annexin-V(FITC)/anti-
CD4(PE)/PI(PC5) and annexin-V(FITC)/anti-CD14(PE)/
PI(PC5). To exclude debris or red blood cells, collected cells
were also stained with anti-CD45 (ECD); their purity was more
than 95%.
Statistical analysis
Septic patients were divided in two groups, those with VAP
and those suffering from other infections. Results were
expressed as means (standard deviation) for parametric varia-
bles and as medians (interquartile range) for non-parametric
variables. Comparisons of baseline quantitative characteris-
tics between groups were performed by the Student's t-test
and of baseline qualitative characteristics by the chi-squared
test. Comparisons of non-parametric quantitative characteris-
tics between groups were performed by the Mann-Whitney U
test.
Both groups of patients were additionally divided in two sub-
groups each, depending on the positive response of mono-
cytes to LPS-stimulation with or without TNFα production. A
more than five-fold increase of TNFα production following
stimulation was considered a positive response. Survival of
two subgroups was estimated by Kaplan-Meier analysis; com-
parisons were performed by the log-rank test.
Apoptosis of each pattern of stimulation of PBMCs was
expressed by means (standard error); comparisons were per-
formed by analysis of variance after Bonferroni correction. Any
value of P below 0.05 was considered significant.
Results
Clinical characteristics of patients enrolled in the study are
presented in Table 1. Other infections included pyelonephritis
(7 patients), primary bacteremia (10 patients), intraabdominal
infection (12 patients), CAP (1 patient) and HAP (2 patients).
No differences were found between patients with VAP and
patients with other infections regarding sex, age, disease
severity (Acute Pathophysiology and Chronic Health Evalua-
tion II score), WBC absolute count and differentiate, as well as
the use of corticosteroids for the treatment of septic syn-
drome. More frequent co-morbidities were chronic obstructive
pulmonary disease, diabetes mellitus, congestive heart failure
and chronic renal failure, but no difference between groups
was observed. Among patients who developed VAP only two
had initially presented with other infections, namely peritonitis
and cholecystitis, and among patients with other infections
only one was primarily hospitalized because of an intraabdom-
inal abscess.
Flow-cytometric data of septic patients with VAP compared to
those with other infections are shown in Table 2. The absolute
number of CD3(+)/CD4(+) cells was significantly lower in
patients with VAP than with other infections (P  = 0.034).
Apoptosis of isolated monocytes was increased in VAP com-
pared with other infections (P = 0.007).
Cytokine release by monocytes upon stimulation with LPS is
shown in Figure 1. Release of both TNFα and IL-6 from mono-
cytes was lower in patients with VAP-related sepsis than with
sepsis related to other types of infection.
Kaplan-Meier analysis of survival of patients subgrouped into
responders and non-responders after stimulation with LPS
revealed that a positive response after stimulation was a detri-
mental factor affecting survival among patients with sepsis
caused by VAP but not in sepsis caused by other infections.
More precisely, among patients with VAP-related sepsis, 28-
day mortality of responders was 25% compared with 60% of
non-responders (P  = 0.045, Figure 2). Among those with
other infections, 28-day mortality of responders was 11.76%
and of non-responders 28.57% (P = 0.245, Figure 2).
To exclude the possibility that results may be related to the
process of mechanical ventilation, patients with non-VAP
related-sepsis were further divided in to two subgroups, those
being intubated and those not being intubated. No difference
in the percentage of CD3(+)/CD4(+) lymphocytes and in the
apoptosis of monocytes was observed between the two sub-
groups. More precisely, median expression of CD3/CD4 on
lymphocytes was 49.60% and 54.66%, respectively (P  =
0.654) and median apoptosis of monocytes was 8.29% and
15.15%, respectively (P = 0.329).
The rate of apoptosis of lymphocytes and of monocytes for
each pattern of stimulation is shown in Figure 3. Stimulation
according to pattern B mimicking pathogenesis of VAP was
accompanied by inhibition of apoptosis of CD4-lymphocytes
and by induction of apoptosis of CD14-monocytes compared
with both patterns A and D.
Discussion
Sepsis is accompanied by dysregulated immune response.
Among patients, those with VAP are considered more com-
promised than others because of the iatrogenic intervention in
mechanical lung defenses due to endotracheal intubation
[19,20]. A recent publication by our group showed that apop-
tosis of monocytes in patients with VAP may play a considera-
ble role in the final outcome of the patient [8]. However, the
point of discussion is whether this innate immune response is
a unique characteristic of sepsis related to VAP or even of sep-
sis not related to VAP. The present study investigated theAvailable online http://ccforum.com/content/13/6/R172
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alterations of innate and of adaptive immune responses in
patients with sepsis due to VAP in comparison to septic
patients with other infections. Every attempt was made to
match both groups of patients according to age, sex, disease
severity and causative pathogens. The latter were Gram-neg-
ative species. It has to be emphasized that in the Greek set-
ting, VAP is mainly caused by Gram-negative pathogens [21].
Flow cytometry analysis revealed two major differences
between sepsis due to VAP and sepsis caused by other infec-
tions. The first difference is the decrease of CD3(+)/CD4(+)
lymphocytes in VAP. Depletion of T-helper lymphocytes in sep-
sis has already been described and attributed to accelerated
apoptosis [22]. In the present study, no difference in the apop-
totic rate of T-helper lymphocytes between the two groups of
patients was shown.
The second major finding is a considerable increase of apop-
tosis of monocytes in patients with VAP. As a consequence of
that phenomenon, immunoparalysis of monocytes, which
occurs normally in sepsis [23,24], is pronounced in VAP com-
pared with other infections. Immunoparalysis was stated by
the inability of monocytes to produce sufficient amounts of
TNFα and IL-6 after stimulation with LPS (Figure 1). Among
patients with VAP, those with monocytes responding to LPS
stimulation presented a survival benefit compared with non-
responders. That was not the scenario for sepsis caused by
other types of infection. Although it was obvious that VAP was
Table 1
Clinical characteristics of patients with sepsis due to VAP (n = 36) and sepsis caused by other infections (n = 32)
VAP Other infections P
Male/female 23/13 14/18 0.099
Age (years) 68.88 (15.57) 64.41 (19.76) 0.300
Sepsis/severe sepsis/septic shock 7/22/7 15/7/10 0.411
APACHE II score 18.25 (4.31) 15.33 (5.03) 0.200
WBCs (/μl) 11530 (1179) 14530 (1469) 0.141
Monocytes 234 (149) 311 (49) 0.422
Lymphocytes 629 (896) 685 (172) 0.922
Neutrophils 8299 (1342) 9180 (1371) 0.642
Use of steroids (n, %) 12 (33.33) 13 (28.12) 0.501
Comorbidities (n, %)
COPD 9 (25.00) 3 (9.38) 0.083
DM 9 (25.00) 6 (18.75) 0.439
CHF 3 (8.33) 7 (21.87) 0.206
CRF 4 (11.11) 2 (6.25) 0.414
Prior infections (n) 2 1
Number of failing organs (n)
Two or more 8 11
Duration of hospitalization (days) 18.93 (20.84) 19.04 (27.90) 0.151
Duration of mechanical ventilation (days) 18.34 (21.11) 26.76 (29.1) 0.525
Bacterial causes (n, %)
P. aeruginosa 12 (33.33) 4 (12.50)
A. baumannii 7 (19.44) 5 (15.62)
K. pneumoniae 3 (8.33) 5 (15.62)
E. coli 1 (2.77) 5 (15.62)
Ent. cloacae 2 (5.55) 2 (6.25)
Values are expressed as means (standard deviation).
APACHE = Acute Physiology and Chronic Health Evaluation; CHF = congestive heart failure; CRF = chronic renal failure; COPD = chronic 
pulmonary obstructive disease; DM = diabetes mellitus; VAP = ventilator-associated pneumonia; WBCs = white blood cells.Critical Care    Vol 13 No 6    Pelekanou et al.
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a situation of profound immunoparalysis, survival was pro-
longed among those patients with adequate monocyte func-
tion (Figure 2).
A question emerging from these results was whether immun-
oparalysis observed among patients with VAP was a result of
their baseline characteristics. The two groups of patients did
not differ in sex, age, disease severity or co-morbidities. The
use of corticosteroids for the treatment of the septic syndrome
was also similar between VAP and non-VAP septic patients.
The presence of prior bacterial infections was rare in both
groups. The possibility that mechanical ventilation could have
acted as a confounding factor was excluded, because no dif-
ference was observed when the percentages of T-helper lym-
phocytes and the apoptosis of monocytes between intubated
and non-intubated non-VAP patients were compared. P. aeru-
ginosa and A. baumannii were more frequently responsible for
VAP than for other infections. This was expected because
these two microorganisms constitute the two major pathogens
of nosocomial pneumonia in Greece [25].
In vitro findings support the hypothesis that one major cause
of immune alterations in patients with sepsis is the type of con-
tact of immune cells with the pathogens. More precisely, in
Table 2
Flow-cytometric data of patients with sepsis due to VAP and sepsis caused by other nosocomial infections
VAP Other infections P
CD3(+)/CD4(+) 208.52 (192) 280.68 (508.7) 0.034
CD3(+)/CD8(+) 114.8 (123.26) 102.49 (244.7) 0.787
CD3(+)/CD(16+56)(+) 18.09 (34.41) 15.11 (49.49) 0.940
*Natural killer cells 26.98 (62.94) 39.61 (45.22) 0.463
CD19(+) 28.00 (70.00) 37.93 (33.82) 0.219
Annexin(+)/CD4(+)/PI(-) 3.16 (4.48) 2.33 (7.64) 0.944
Annexin(+)/CD8(+)/PI(-) 3.74 (8,71) 6.47 (15.71) 0.269
Annexin(+)/PI(-) of isolated monocytes 20.62 (28.11) 12.19 (22.98) 0.007
*Natural killer cells were defined as CD3(-)/CD(16+56)(+). Values are expressed as median (IQR) absolute numbers for CD3(+)/CD4(+), 
CD3(+)/CD8(+), CD3(+)/CD(16+56)(+), natural killer and CD19(+) cells and as median (interquartile range) percentages for Annexin(+)/
CD4(+)/PI(-), Annexin(+)/CD8(+)/PI(-) and Annexin(+)/PI(-) of isolated monocytes. VAP = ventilator-associated pneumonia.
Figure 1
TNFα and IL-6 production from the supernatants of monocytes TNFα and IL-6 production from the supernatants of monocytes. Concentrations of TNFα and IL-6 of supernatants of monocytes of patients with sep-
sis due to ventilator-associated pneumonia (VAP) and patients with sepsis caused by other nosocomial infections. The asterisk denotes significant 
difference between the two groups of patients. (P = 0.008 for TNFα; P = 0.003 for IL-6). LPS = lipopolysaccharide; SE = standard error.Available online http://ccforum.com/content/13/6/R172
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patients with VAP the immune system is gradually exposed to
the pathogen. The latter is entering the airways through aspi-
ration of the oropharyngeal flora and then steadily increases to
an amount able to induce VAP. As a consequence, the
immune system is gradually exposed to sequentially increased
bacterial inocula, which leads to decreased apoptosis of CD4-
lymphocytes and to increased apoptosis of CD14-monocytes
(Figure 3, pattern B). When VAP evolves abruptly, similar alter-
ations are not seen (Figure 3, pattern C). This is also the case
with bacteremia (Figure 3, pattern D).
The in vitro experiment was based on the assumption that VAP
supervenes as a result of gradual and continuous exposure of
the innate immune system to the pathogen while non-VAP sep-
sis is the result of an abrupt stimulation of the innate immune
system. The response of PBMCs of healthy volunteers may dif-
Figure 2
Comparison of survival of septic patients Comparison of survival of septic patients. Comparison of survival of septic patients due to ventilator-associated pneumonia (VAP) and patients with 
sepsis caused by other infections depending on the presence or absence of response of their monocytes to stimulation with lipopolysaccharide.
Figure 3
Apoptosis of CD14-monocytes and of CD4-lymphocytes of healthy volunteers Apoptosis of CD14-monocytes and of CD4-lymphocytes of healthy volunteers. Induction of apoptosis of CD14-monocytes and inhibition of apopto-
sis of CD4-lymphocytes of healthy volunteers according to four different patterns of stimulation by isolates of Acinetobacter baumannii and of Pseu-
domonas aeruginosa. A = un-stimulated controls; B = three-step stimulation mimicking pathogenesis of ventilator-associated pneumonia (VAP); C = 
abrupt stimulation with pathogens of VAP; and D = abrupt stimulation mimicking pathogenesis of bacteremia. Asterisks denote significant difference 
between patterns B and D and between patterns B and A. SE = standard error.Critical Care    Vol 13 No 6    Pelekanou et al.
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fer from those of PBMCs of septic patients. A number of fac-
tors participate to the interactions between bacteria and the
immune system, such as virulence genes or pattern recogni-
tion receptors, whose role was not studied in our setting. Fur-
ther investigation is mandatory in order to clarify our
hypothesis about the pathogenesis of VAP.
Conclusions
The presented findings reveal that innate and adaptive immune
responses differ considerably between sepsis due to VAP and
sepsis due to other types of nosocomial infection. VAP is char-
acterized by substantial decrease of CD4-lymphocytes and
immunoparalysis of monocytes in contrast to other infections.
The mechanism of bacterial pathogenesis of VAP may help
explain these differences. The latter could constitute a novel
therapeutic target for the management of the septic patient
with VAP.
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Key messages
￿  Sepsis due to VAP is characterized by decrease of 
CD3/CD4(+) lymphocytes and immunoparalysis of 
monocytes compared with sepsis caused by other 
nosocomial infections.
￿  The mechanism of bacterial pathogenesis of VAP 
seems to play a crucial role in the explanation of these 
differences.